|Videos|July 18, 2022
Basal Cell Carcinoma Clinical Pearls
Author(s)Jennifer L. Atlas, MD, Shahab Babakoohi, MD
Drs Babakoohi and Atlas share clinical pearls for community oncologists on treating basal cell carcinoma.
Advertisement
Advertisement
Related to this article
Adding intismeran autogene to pembrolizumab cut the risk of recurrence and distant metastasis in resected high-risk melanoma in INTerpath-001.
Phase 1 data support continued investigation of roginolisib in advanced cancers, including metastatic uveal melanoma.
Advertisement
Advertisement
Trending on OncLive
1
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
4
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
5